| Name | Title | Contact Details |
|---|
The Federation of American Hospitals (FAH), founded in 1966, is the national representative of investor-owned or managed community hospitals and health systems throughout the United States and one of Washington, DC`s most respected and influential health policy and advocacy organizations. Dedicated to a market-based philosophy, we provide representation and advocacy on behalf of our members to Congress, the Executive Branch, the judiciary, media, academia, accrediting organizations and the public. The Federation of American Hospitals serves its members as a clearinghouse for information about the nation`s most vital health policy issues. These include Medicare and Medicaid, the uninsured, health care quality, patient safety, health information technology, medical liability insurance reform, rural health care, long-term hospital care, inpatient psychiatric care, hospital emergency preparedness, antitrust, compliance, the health care workforce shortage, privacy and confidentiality, tax issues, and rehabilitation services, among other important issues.
Atkins Nutritionals is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prince George Hospice Society is a Prince George, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.